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Basal cell carcinomas are the most common form of
skin cancer. Tazarotene is a retinoic acid receptor selec-
tive retinoid that upregulates a tumor suppressor, tazar-
otene-induced gene 3 (TIG-3), in keratinocytes and
psoriasis. Expression of TIG-3 in basal cell carcinomas
was studied in an opened-label pilot biomarker study of
22 patients with basal cell carcinomas who applied ta-
zarotene 0.1% gel for up to 12 wk prior to excision.
Nineteen paired baseline and treated specimens were
compared using immunohistochemistry and in situ hy-
bridization. Compared to overlying normal epidermis,
TIG-3 protein and mRNAwere decreased in 14 and 18
of 19 basal cell carcinomas (74% and 95%), respectively
(po0.001). Tazarotene treatment was associated with in-
creased TIG-3 protein and mRNA expression in basal
cell carcinomas compared to baseline levels (pp0.001
and p¼ 0.028, respectively). Sixty percent of basal cell
carcinomas treated with tazarotene decreased in size
by at least 25%. Ten of 19 lesions improved histologi-
cally, including three complete responses. There was a
correlation between the increased expression of TIG-3
protein and histologic improvement (p¼ 0.020), sug-
gesting that suppression of TIG-3 may underlie the de-
velopment of basal cell carcinomas. This association
suggests that reversal of TIG-3 expression may help to
explain the mechanism of retinoid action in epidermal
di¡erentiation and chemoprevention. Key words: chemo-
prevention/retinoids/skin cancer/translational research/tumor
suppressor. J Invest Dermatol 121:902 ^909, 2003
B
asal and squamous cell carcinomas arise from epider-
mal keratinocytes, and comprise the majority of skin
cancers, the most common malignancy in human
(Kanjali and Duvic, 1998). A complex genetic pro-
gram underlying normal epidermal di¡erentiation
leads to terminal di¡erentiation, i.e., keratinocyte apoptosis and
barrier formation (Eckert et al, 1997). Epidermal carcinogenesis is
associated with ultraviolet-light-induced genetic mutations in the
tumor suppressor, p53 (Brash et al, 1996; Ananthaswamy et al,
1997), and sonic hedgehog signaling pathway proteins Lacour,
2002; Tojo et al, 2002). Psoriasis is a nonmalignant, epidermal hy-
perproliferation induced in genetically susceptible individuals by
reversible cellular in£ammation and cytokine expression (Veal
et al, 2002). The cytokine inducible nuclear transcription factor,
NF-kB, is implicated in the control of epidermal proliferation
and may be common to both psoriasis and skin cancer (Seitz
et al, 1998).
Vitamin A analogs or retinoids have been used clinically
to treat carcinomas arising from oral mucosa and skin (Kraemer
et al, 1988) as well as for chemoprevention of second primary
cancers in head and neck and lung cancer (Lippman et al, 1996).
A clear understanding of their speci¢c mechanism(s) of action
in cancer, however, has lagged behind clinical application. Reti-
noids bind to tissue-speci¢c retinoid receptors: the retinoic acid
receptor (RAR-a, RAR-b, and RAR-g) and retinoid X receptor
(RXR-a, RXR-b, and RXR-g). RAR and RXR are ligand-
dependent transcription factors that form homodimers or hetero-
dimers, bind to DNA sequences or response elements, and also
interact with other transcription factors to modulate the expres-
sion of genes (Chambon, 1995). Retinoids and their receptors
in£uence expression of keratin genes in epidermal cells (Aneskie-
vich and Fuchs, 1992).
To better understand retinoid action, cells in cell culture sys-
tems have been treated with receptor-selective retinoids, and a pa-
nel of genes that are induced or reduced during treatment with
selective retinoids have been isolated (Balmer and Blomho¡,
2002). Tazarotene is a synthetic RAR-b/g selective retinoid
approved for the topical treatment of acne and psoriasis (Elder
et al, 1992;Weinstein et al, 1997; Balmer and Blomho¡, 2002;Web-
ster et al, 2002). Di¡erential display PCRwas employed to identi-
fy mRNAs that were induced by tazarotene treatment of human
keratinocytes, and over 30 genes, called RARRES for retinoic
acid receptor responders or TIGs for tazarotene-induced genes,
have been isolated (Nagpal et al, 1996a; 1996b; 1997; Thacher et al,
1996; DiSepio et al, 1998; Duvic et al, 1998; Jing et al, 2002). Only
few of these genes have been further characterized. TIG-1, a
membrane bound protein recently implicated as a tumor suppres-
sor, is diminished in prostate carcinoma cell lines and tumors
(Nagpal et al, 1996a; Jing et al, 2002).
Our laboratory has been interested in the tazarotene-induced
gene 3 (TIG-3) because it is homologous to H-rev, a known class
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II tumor suppressor that inhibits growth of cancer cell lines
in vitro (Hajnal et al, 1994; DiSepio et al, 1998). TIG-3 gene was
localized to chromosome 11q23, a site of loss of heterozygosity
in several cancer lines (Murakami et al, 1998; Di Iasio et al, 1999;
Duvic et al, 2000). Expression studies of TIG-3 have shown that
the carboxy-terminus is required for cell location and growth in-
hibition (Deucher et al, 2000). In breast cancer cell lines, growth
inhibition by retinoid treatment correlates with TIG-3 inducibil-
ity suggesting a causal relationship (DiSepio et al, 1998).With re-
gard to epidermal hyperproliferation and development of skin
cancers, we previously found that TIG-3 expression is diminished
in psoriasis lesions and basal cell carcinomas (BCC), and is signif-
icantly lower in advanced squamous cell carcinomas (DiSepio
et al, 1998; Duvic et al, 2000).
BCC are common, indolent skin tumors arising from kerati-
nocytes in the interfollicular basal epidermis, hair follicles, and
sebaceous glands, and they can become locally invasive and cause
signi¢cant mortality (Kruger et al, 1999). Of interest, topical tazar-
otene gel used for 8 mowas previously reported to induce clinical
remission in 16 of 30 BCC (53%), but the mechanism of action
and histology were not addressed (Peris et al, 1999). To determine
whether a relationship exists between application of topical tazar-
otene, clinical improvement in BCC, and induction of TIG-3, we
performed a prospective clinical molecular biomarker trial asses-
sing TIG-3 expression in patients’ skin. All growth patterns of
BCC demonstrated decreased or loss of expression of TIG-3 pro-
tein and mRNA that was reversed in vivowith treatment of BCC
with tazarotene for up to 12 wk.
MATERIALS AND METHODS
Patients and study design The experiments conducted in this study
were done in accordance with Helsinki principles and had institutional
IRB approval. Twenty-two adults (shown in Table I) with 35 histo-
logically proven BCC signed approved informed consent to participate
in a prospective, opened label pilot study conducted at a single institution.
Two weeks after a 3 mm diagnostic punch biopsy of the BCC was
performed, patients were instructed to apply tazarotene 0.1% gel (kindly
provided by Allergan, Irvine, CA) to BCC tumors once daily for 6^12
wk. The lesions were clinically evaluated every 4 wk for tumor response
using bidimensional measurements and photography. Oncologic responses
were graded as CCR (complete clinical disappearance of tumor), PR
(450% partial reduction in size), MR (minor response of 25%50%
reduction in size), SD (stable disease, 0%^25% decrease) or progression
(PD, increase in tumor size). All BCC were removed by Mohs
micrographic surgery (Rapini, 1999) and the tissue was examined
histologically. The degree of local irritation was assessed as absent or
present (mild, moderate, or severe) (Table II).
Histopathology Skin specimens were ¢xed in 4% paraformaldehyde,
embedded in para⁄n, sectioned, and stained as previously described
(Stoler et al, 1988; Duvic et al, 2000). BCC were graded as having one of
four growth patterns: super¢cial (including multicentric), nodular
(including micronodular), in¢ltrative (including morpheaform), or mixed
(including a combination of any two or all of the above types or adenoid
di¡erentiation) (Rippey, 1998). Histopathology was evaluated in all 35
lesions (Table I). Nineteen paired pre- and post-treatment skin biopsy
specimens from 14 patients were available and of su⁄cient quantity and
quality to evaluate TIG-3 protein and mRNA expression (Table III).
Normal adjacent skin from tumors numbered 4, 5, and 7 at baseline as
well as normal control skin from six adult mastectomy patients were used
as the positive controls. All BCC were excised with Mohs micrographic
surgery at the end of the study and normal healing was observed.
Immunohistochemistry (IHC) IHC was performed as previously
described (Duvic et al, 2000). TIG-3 rabbit polyclonal antibody raised to
recombinant TIG-his tag protein1^164 was a gift from Dr Richard Eckert
and Dr Anne Deucher, Department of of Biochemistry, Case Western
Reserve, Cleveland, OH (Deucher et al, 2000). The primary antibody was
at a dilution of 1:500 and was detected with horse antirabbit secondary
antibody at 1:100 using a Vector Stain ABC kit (Vector Laboratories,
Burlingame, CA). Primary antibody was omitted as a negative control.
In situ hybridization (ISH) ISH was conducted using plasmid (pAGN-
TIG-3) with the 600 bp 30 TIG-3 cDNA in reverse orientation as
previously described (DiSepio et al, 1998; Duvic et al, 2000). One
microgram of cDNA template was linearized with Not I or Hind III and
transcribed using either Sp6 or T7 polymerase to yield antisense and sense
(negative control) riboprobes, respectively. Riboprobes were transcribed
in the presence of UTP-digoxigenin using a Genius 4 kit, according to
the manufacturer’s instructions (Roche, Indianapolis, IN). The probe
concentrations were estimated using a dot-blot method and serial
dilutions with a Dig DNA labeling and detection kit (Roche). ISH was
performed as described with the modi¢cation of using active DEPC
water and using ethanol to reduce background staining (Duvic et al, 2000;
Xu et al, 2001). Baseline and treated tissue sections with normal skin
controls were analyzed simultaneously for expression of TIG-3 mRNA to
ensure reliable comparison.
Semiquantitative analysis of staining intensity The staining intensity
was evaluated by either IHC or ISH, graded by two separate blinded
observers, and recorded for each specimen of normal control skin, tumor,
and adjacent skin. For IHC, staining intensity was graded as 0 (no
staining), 1 (faint staining, light brown), 2 (light staining, yellow brown),
3 (moderate brown), 4 (dark brown), or 5 (dark black staining obscuring
the architecture). For ISH, staining intensity was graded as 0 (no
staining), 1 (light blue, faint staining), 2 (blue staining), 3 (moderate
staining, purple color), 4 (strong, very deep purple), and 5 (dark black
staining obscuring the architecture). The scales are shown in Fig 1.
Statistical analysis Means, standard deviation, frequency, and summary
data are given whenever appropriate. Fisher’s exact test, the w2 test, and the
general linear model (GML) univariate procedure (SSPS, version 11.5 for
Windows) were used to assess the association between two binary
variables, such as the association between the clinical responses and the
modulation of TIG-3. A two-tailed paired sample t test was used to
compare TIG-3 expression between BCC lesions and the overlying
epidermis or from BCC lesions before and after treatment. Two-sided
p-values were determined in all analyses.
RESULTS
Clinical response and safety As shown in Table I, 11 lesions
from 10 patients were treated with topical tazarotene 0.1% gel
for less than 6 wk and 24 lesions from 12 patients were treated
for 6^12 wk. The tumors ranged in size from 0.3 0.3 to
5.52.0 cm with a median dimension of 1.01.5 cm. Twenty-
Table I. Patient demographics and response to tazarotene
treatment
Characteristics Patients with BCC
Age ^ y n¼ 22
Median 67
Range 5085
Gender ^ no. of patients (%) n¼ 22
Female 3 (14)
Male 19 (86)
Histologic patterns ^ no. of lesions (%) n¼ 35
Super¢cial 7 (20)
Nodular 15 (43)
In¢ltrative 2 (6)
Mixed 11 (31)
Clinical response ^ no. of lesions (%) n¼ 35
Complete clinical response 1 (3)
Partial response (450%) 9 (26)
Minor response (425%o50%) 11 (31)
Stable disease (40%o25%) 12 (34)
Progressive disease 1 (3)
Lost follow-up 1 (3)
Duration of treatment ^ no. of patients (no. of lesions) 22 (35)
p6 wk 10 (11)
46^12 wk 12 (24)
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one of the 35 BCC treated (60%) showed a reduction of 25% or
more in tumor size (CCRþPRþMR) at the time of surgical
excision. Nine of 35 lesions (26%) had partial regression (PR).
An example of a responding patient is shown in Fig 2. Eleven
lesions (31%) exhibited minor responses (MR), 12 BCC (34%)
were judged as stable (SD), and only one (3%) progressed
slightly in size during therapy. One patient was lost to follow-
up. In the group of BCC treated for less than 6 wk, one was
judged CCR, one partially regressed, and ¢ve had minor
responses. The overall response rate was eight PR and six MR
for 24 BCC treated for 6^12 wk.
Figure1. TIG-3 protein and mRNA expression are decreased in all types of BCC compared to the overlying epidermis. Four BCC of repre-
sentative histology (super¢cial, nodular, in¢ltrative, and mixed) were studied using hematoxylin and eosin staining for morphology (top row: a, d, g, j), IHC
for TIG-3 protein (middle row: b, e, h, k), and ISH for mRNA expression (bottom row: c, f, i, l) as described in Materials and Methods. Black arrows indicate tumor
areas and empty arrows indicate the overlying epidermis. The boxed inserts in (a), (b), and (c) indicate where super¢cial BCC is budding from the epidermis.
Scale bar: 50 mm.
Figure 2. One female patient with a nodular
BCC on the tip of the nose. (a) Baseline photo-
graph taken 1 wk after biopsy on 4-03-01. (b)
After 1 mo of topical tazarotene gel 0.1% applica-
tion on 5-02-01 prior to surgical removal.
Table II. Symptoms or signs reported with topical tazarotene
gel application
Symptom or sign Frequency among patients (n¼ 22)
Burning or itching 1 (5%)
Telangectasias 6 (27%)
Erythema or in£ammation 10 (45%)
Flaking, excoriations 3 (14%)
Erosions or ulcerations 4 (18%)
Crusting, scabbing 14 (63%)
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As shown in Table II, local symptoms and side-e¡ects
commonly experienced included burning or itching, erythema,
and irritation. Ulceration or crusting could not be distinguished
from tumor ulceration induced by therapeutic e¡ect. Irritation
was reduced by discontinuing the medication for a few days.
Histologic improvement of BCC tumors after topical
tazarotene treatment The histology of 19 pairs of BCC from
14 patients was evaluated at baseline and following topical
tazarotene treatment (Table III). At baseline, BCC were graded
as super¢cial (n¼ 4), nodular (n¼ 8), in¢ltrative (n¼1), or
mixed histology (n¼ 6). Mixed lesions included super¢cial plus
nodular BCC (n¼ 3), nodular plus in¢ltrative BCC (n¼ 2), and
nodular with adenoid di¡erentiation (n¼1). Representative
specimens are shown in the upper row of Fig 1. Ten of 19 BCC
specimens (53%) were histologically improved after treatment
with topical tazarotene, compared to baseline. Three BCC (nos.
13, 15, 16) were histologically clear without remaining tumor at
resection (Tables III, IV). Five nodular BCC (nos. 3, 8, 12, 17, 19)
at baseline were judged as having super¢cial histology after
treatment, as shown in Fig 3 for tumor no. 3. Tumor no. 1
showed a nodular and in¢ltrative pattern at baseline with
nodular and super¢cial histology after treatment.
One in¢ltrative BCC of the nasal ala (lesion 5) was completely
resolved by clinical examination, but in¢ltrative tumor cells were
still present on histologic examination (not shown). Six lesions
(32%) had unchanged histology. Three BCC (16%) had an
in¢ltrative pattern on the deeper resection that had not been
appreciated in the more super¢cial baseline specimen.
TIG-3 protein is signi¢cantly reduced in BCC compared
to overlying normal epidermis at baseline As shown in
Fig 4, yellow-brown staining for TIG-3 protein is stronger
in the suprabasal layers versus the basal layer of normal skin from
control subjects (n¼ 6). The cell cytoplasm stains homogene-
ously in keratinocytes, including those of the appendages
(not shown). The staining intensity of TIG-3 protein is
diminished in both suprabasal and basal layers of the epidermis
adjacent to BCC tumors (n¼ 3) compared to normal control
epidermis.
As shown inTable III and Fig 5, prior to treatment the mean
level of TIG-3 protein in BCC at baseline (1.5370.69) was 2.17-
fold less than that in the paired overlying epidermis (3.3271.38)
(po0.001). Fourteen of 19 BCC (74%) showed reduced levels of
TIG-3 protein. One super¢cial lesion (5%) showed complete
loss of TIG-3 protein expression and 13 of 19 BCC (69%) had
diminished TIG-3 protein expression compared to overlying
normal epidermis. Decreased TIG-3 protein was observed in all
histologic types of BCC including two super¢cial, ¢ve nodular,
one in¢ltrative, and ¢ve mixed tumors (middle row, Fig 1). In
¢ve of 19 BCC (26%), TIG-3 protein expression was similar to
overlying epidermis but reduced compared to normal skin.
TIG-3 protein is signi¢cantly increased in BCC after topical
tazarotene treatment TIG-3 protein expression in the over-
lying epidermis was similar before and after treatment with
tazarotene gel (3.3271.38 before vs 3.0571.18 after, p¼ 0.399 by
paired t test, n¼19). In contrast, the mean level of TIG-3 protein
(2.4470.81) was higher after therapy than that at baseline
(1.5370.69) (po0.001 by paired t test, n¼16). Eleven of 16 BCC
Table IV. Growth patterns of BCC before and after topical
tazarotene treatment
No. of BCC lesions/total (%)
Growth patterns of BCC Before treatment After treatment
Super¢cial 4 (21%) 7 (37%)
Nodular 8 (42%) 2 (11%)
In¢ltrative or morpheaform 1 (5%) 1 (5%)
Mixed 6 (32%) 6 (32%)
No tumor ^ 3 (16%)
Total 19 19
Figure 3. Improvement in BCC histology correlates with increased
TIG-3 expression following topical tazarotene. Tumor no. 3
(Table III) is shown at baseline (a, b, c) and after tazarotene treatment
(d, e, f). Hematoxylin and eosin staining (a, d) is for histology,TIG-3 pro-
tein expression is stained by IHC (b, e), and TIG-3 mRNA expression is
stained by ISH (c, f). Scale bar: 50 mm.
Figure 4. TIG-3 expression of protein and mRNA is lower in the
epidermis adjacent to BCC tumors compared to the normal epider-
mis. IHC staining and ISH were used to detect the presence of TIG-3 pro-
tein (middle row) and mRNA signal (bottom row). Scale bar: 50 mm.
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(69%) with residual tumor at excision showed increased TIG-3
protein expression after treatment, whereas ¢ve of 16 BCC
(31%) had no change. Post-treatment TIG-3 protein expression
in BCC was not signi¢cantly di¡erent from paired, treated,
overlying epidermis (Table III, Fig 5). After treatment,
TIG-3 protein was only lower in eight of 16 BCC (50%)
compared to overlying epidermis, as opposed to 14 of 19 BCC
with lower expression at baseline (74%, p¼ 0.021 by w2 test)
(Table III).
Three of 19 paired lesions showed complete histologic clearing,
and in these the overlying treated epidermis was graded as 5
(most intense) in two and 3 (moderate) in the third.
TIG-3 mRNA is signi¢cantly reduced in BCC compared to
overlying normal epidermis at baseline As evaluated by
ISH, TIG-3 mRNA stained blue-purple in the cytoplasm and
was homogeneously distributed in normal epidermis and
appendages. TIG-3 mRNAwas diminished in the basal layer of
the epidermis adjacent to tumors, compared to normal control
epidermis (Fig 4). TIG-3 mRNA in the basal layer of epidermis
overlying BCC was less than that in normal control epidermis.
As shown in Table III and Fig 5, the mean level of TIG-3
mRNA BCC (1.0570.78) was 2.66-fold less than that in
overlying epidermis (2.7971.13, po0.001 by paired t test) at
baseline. TIG-3 mRNA was reduced in 18 of 19 BCC tumors
(95%) compared to the overlying epidermis (Table III). Four of
19 BCC (21%) had complete absence of TIG-3 mRNA and 14
(74%) had decreased TIG-3 expression compared to overlying
epidermis. These changes were irrespective of tumor histology
(Fig 1, bottom row). One super¢cial BCC of the trunk (lesion 11)
had equal TIG-3 mRNA staining to the paired epidermis. As
shown for lesion 1 in Fig 6, nuclear staining was observed in
some tumor cells with decreased or absent cytoplasmic staining.
TIG-3 mRNA signi¢cantly increased in BCC after topical
tazarotene treatment The mean level of TIG-3 mRNA did
not change in overlying normal epidermis from baseline to
post-treatment (2.7971.13 vs 2.6371.42, respectively, p¼ 0.718
by paired t test). In BCC TIG-3 mRNA was increased from
1.0570.78 at the baseline to 1.8171.11 following treatment
(po0.028 by Student paired t test) (Table III, Fig 5) although
TIG-3 mRNA in BCC was still lower than in overlying
epidermis (2.6371.42) (p¼ 0.001) (Table III, Fig 5). Ten of
16 BCC (63%) were found to have increased TIG-3 mRNA
expression, ¢ve tumors (31%) had stable TIG-3 mRNA
expression, and one super¢cial BCC had decreased TIG-3
mRNA after treatment. After treatment TIG-3 mRNA was
lower in 11 of 16 BCC (69%) compared to paired overlying
epidermis, in contrast to baseline where 18 of 19 BCC were lower
in TIG-3 mRNA (95%, p¼ 0.204 by w2 test) (Table III).
In three BCC with complete histologic clearing, the overlying
epidermis was graded by ISH as 5 (most intense) in one and 3
(moderate) in two following therapy.
Relationship between TIG-3 expression and clinical and
histologic improvement Twelve of 19 pairs of BCC (63%)
had clinical responses to treatment (CCR, 1; PR, 5; MI, 6) and
seven did not respond (SD, 6; PD, 1). Eleven of 16 BCC (69%)
evaluated after therapy had increased TIG-3 protein expression
as above. Seven of 11 lesions with upregulated expression of
TIG-3 protein after treatment had clinical responses (64%),
compared to two of ¢ve lesions (40%) without TIG-3 protein
upregulation (p¼ 0.071, by Fisher’s two-sided exact test).
Similarly, 10 of 16 BCC (63%) had increased TIG-3 mRNA as
above, and seven of 10 lesions (70%) with increased TIG-3
mRNA had clinical responses, compared with two of six lesions
(33%) without TIG-3 mRNA upregulation (p¼ 0.059, by Fisher’s
two-sided exact test).
Ten of 19 paired lesions (53%) had histologic improvement to
treatment as mentioned before (Table IV). Six of 11 lesions
(54.5%) with upregulated expression of TIG-3 protein after
treatment had histologic improvement, compared with one of
¢ve lesions (20%) without TIG-3 protein upregulation. There
was a signi¢cant correlation between the increased expression
of TIG-3 protein (but not TIG-3 mRNA) and histologic
improvement (p¼ 0.020, by GLM model univariate).
Figure 5. Mean level of TIG-3 protein and mRNA signi¢cantly di-
minishes in BCC at baseline and increases after tazarotene treat-
ment. The intensity of staining for TIG-3 protein by IHC (left four bars, a,
b, c, and d) and the intensity of staining forTIG-3 mRNA by ISH (right four
bars, e, f, g, and h) were graded using a semiquantitative scale of 0^5, as de-
scribed in Materials and Methods. The mean intensities of staining in BCC
(black bars) were compared with the overlying epidermis (white bars) at base-
line (a vs b and e vs f) and after the treatment (c vs d and g vs h). The mean
intensities of staining in BCC (black bars) at baseline were compared with
those after treatment (a vs c and e vs g). Figure 6. TIG-3 mRNA staining in nuclei seen in BCC lesions with
diminishedTIG-3 mRNA. Hematoxylin and eosin staining is for histol-
ogy (a); IHC staining and ISH were used to detect the presence of TIG-3
protein (b) and mRNA (c). The speci¢city of the binding of the antisense
riboprobe was veri¢ed by using sense probe as a negative control (d).TIG-3
mRNA signal in nuclei was seen in tumor no. 1 BCC with diminished
TIG-3 mRNA (e). Scale bar: 50 mm.
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DISCUSSION
Our study analyzed the expression of TIG-3 protein and mRNA
levels in paired BCC before and after treatment with 0.1% topical
tazarotene gel. Consistent with a pilot study involving only three
BCC (Duvic et al, 2000), TIG-3 protein and mRNAwere selec-
tively lost or decreased in BCC.We also report for the ¢rst time
that tazarotene application was associated with reversal of the di-
minished expression of TIG-3 protein and mRNA in human
subjects’ BCC tumors. These data support the hypothesis that
TIG-3 (RARRES-3) is a RAR-induced tumor suppressor and
a potential target for therapeutic and chemoprevention in vivo
for skin cancer as well as tumor cell lines (DiSepio et al, 1998;
Duvic et al, 2000).
The mechanism resulting in diminished TIG-3 expression in
BCC is unknown. Reversibility by treatment in psoriasis and
skin cancer cells and lesions suggests the importance of modula-
tion of gene transcription rather than genetic deletions (DiSepio
et al, 1998; Duvic et al, 2000). Mutations in TIG-3 coding se-
quences in squamous cell carcinoma cells and head and neck
squamous cell carcinoma cell lines have not been detected
(Schulz, manuscript in preparation). Di¡erences have been ob-
served in the methylation patterns of the TIG-3 promoter from
squamous carcinoma cell lines, which could a¡ect transcription.
This study, conducted in vivo, also supports the reversibility of
TIG-3 expression in human tumors after topical tazarotene appli-
cation. Suppressed expression of retinoid receptors, especially
RAR-b, is reported in actinic keratosis, squamous cell carcinoma,
and premalignant oral lesions, and can be upregulated by isotre-
tinion (Lotan et al, 1995; Xu et al, 2001).The expression of retinoid
receptors in BCC has not been fully explored.
TIG-3 or RARRES-3 was ¢rst identi¢ed from tazarotene-
treated keratinocytes using di¡erential display PCR to amplify
and identify mRNA (DiSepio et al, 1998). TIG-3 has been shown
to be inducible by RAR-selective retinoids in primary human
keratinocytes and TIG-3 transfection results in growth inhibition
of tumor cells in vitro (DiSepio et al, 1998; Deucher et al, 2000).
Although we previously showed that TIG-3 mRNA expression
was induced in psoriatic lesions after application of topical tazar-
otene 0.1% gel for 2 wk (DiSepio et al, 1998; Duvic et al, 2000),
this is the ¢rst demonstration that reversal of diminished TIG-3
expression in BCC is associated with topical application of
tazarotene.
Peris et al (1999) ¢rst demonstrated that topical tazarotene gel
0.1% induced clinical remission in 53% of BCC treated for 8
mo, without histologic con¢rmation in all cases. Our results are
similar with 21 of 35 BCC (60%) treated for up to 12 wk show-
ing a clinical improvement or reduction in tumor size; only one
tumor progressed. Histologic evaluation of tumors following
therapy is important as one tumor with complete clinical clearing
was still present microscopically and three tumors called PRwere
actually clear by histology. Of importance, our study showed a
signi¢cant correlation between increased TIG-3 protein and his-
tologic improvement and the treatment with tazarotene. It is
possible that TIG-3 protein contributes to inhibition of hyper-
proliferation, induction of di¡erentiation, and the suppression of
malignant phenotype, and is thus causally linked to the histologic
outcome.
Epidermal carcinogenesis is a complex process that involves
multiple, sequential genetic changes in oncogenes and tumor
suppressors (Hanahan andWeinberg, 2000; Lacour, 2002). Ultra-
violet-light-induced mutations in the tumor suppressor p53 are
found commonly in skin cancers and from the adjacent ¢eld of
normal skin (Brash et al, 1996; Ananthaswamy et al, 1997). TIG-3
protein and mRNAwere detected in normal skin from control
subjects, but TIG-3 protein was lost in 5% and decreased in 69%
of all BCC, regardless of growth pattern. TIG-3 mRNAwas ab-
sent in 21% of BCC and diminished in 74% of BCC. One
would not expect TIG-3 protein to remain in the absence of
mRNA; however, in situ hybridization and immunohistochem-
ical techniques are at best only semiquantitative. In addition, re-
tinoids may a¡ect post-transcriptional regulation of epidermal
proteins, i.e., keratin 19 mRNA levels (Crowe, 1993).Whereas ta-
zarotene treatment was associated with higher expression of TIG-
3 in BCC, the overlying epidermis appeared to have a steady level
of expression. But the overlying skin was still diminished inTIG-
3 compared to control normal skin, suggesting a ¢eld e¡ect. Ag-
gressive squamous cell carcinomas also have diminished TIG-3
expression, with complete loss found in the most aggressive tu-
mors (Duvic et al, 2000).The ¢nding of diminished TIG-3 in skin
cancer and psoriatic epidermal hyperproliferation may be asso-
ciated with a ¢eld e¡ect in areas where tumors arise, similar to
p53 (Brash et al, 1996). In this study, 36% and 30% of BCC with-
out de¢ned clinical responses also had increased TIG-3 protein
and mRNA levels, respectively. In contrast to the Peris trial of
8 mo, BCC in this trial received treatment for only up to
12 wk, and these lesions might have showed clinical responses
with longer treatment.
Tazarotene is known to modulate other genes in addition to
TIG-3. Both sporadic and hereditary BCC are associated with
mutations in the sonic hedgehog pathway leading to increased
expression of a transcription factor, gli-1 (Green et al, 1998; Tojo
et al, 2002).Whether gli-1 can modulate TIG-3 expression is un-
known. Tazarotene also induces the suppressor TIG-1, which has
been reported to be diminished in prostrate cancer but has not
yet been studied in skin cancer (Jing et al, 2002).
Tazarotene gel was well tolerated even when applied to biopsy
sites. The side-e¡ects were related to irritation at the application
site and were observed in a majority of patients. It is possible that
retinoid irritation could also induce TIG-3 expression or partici-
pate in clinical response of tumors. TIG-3 is homologous to the
tumor suppressor H-rev that can be induced by g interferon (Ku-
chinke et al, 1995). Psoriatic lesions have high g interferon levels
with low TIG-3, however (DiSepio et al, 1998; Breuer-McHam
et al, 2000; Duvic et al, 2000). Topical imiquimod therapy clears
some BCC by local induction of cytokines (Beutner et al, 1999)
and tazarotene also regulates the expression of in£ammatory cy-
tokines (Esgleyes-Ribot et al, 1994; Nagpal et al, 1996b; Duvic et al,
1997; 1998).
Diminished expression of TIG-3 protein and mRNA was
found in all histologic types of BCC and increased expression
was found to be associated with clinical and histologic improve-
ment. We speculate that loss of TIG-3 may play a role in skin
cancer development as it is growth inhibitory in carcinoma lines
in vitro (DiSepio et al, 1998; Deucher et al, 2000). Restoration of
TIG-3 protein and mRNA levels could mediate the clinical
response to tazarotene (Peris et al, 1999) and other RAR reti-
noid compounds through modulating epidermal di¡erentiation
and growth inhibition. TIG-3 may be a useful intermediate
biologic marker for retinoid chemoprevention and treatment
studies.
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